{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:36Z","timestamp":1790837076290,"version":"4.1.0"},"reference-count":171,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.pharmthera.2013.11.006","type":"journal-article","created":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T06:36:10Z","timestamp":1385188570000},"page":"72-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The cardioprotective effects of mineralocorticoid receptor antagonists"],"prefix":"10.1016","volume":"142","author":[{"given":"T.N.A.","family":"van den Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard A.","family":"Rongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg M.","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Deinum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Hausenloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels P.","family":"Riksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.11.006_bb0005","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.amjcard.2004.03.015","article-title":"Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy","volume":"93","author":"Abiose","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0960-0760(95)00196-4","article-title":"Analysis of the human gene encoding the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase","volume":"55","author":"Agarwal","year":"1995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0015","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1016\/0303-7207(94)90176-7","article-title":"Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme","volume":"105","author":"Albiston","year":"1994","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0020","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.111.052126","article-title":"Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling","volume":"125","author":"Anzai","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0025","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.4238\/2012.August.31.10","article-title":"11beta-hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease","volume":"11","author":"Atalar","year":"2012","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCHEARTFAILURE.112.000003","article-title":"Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Bapoje","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/01.HYP.0000025879.29822.24","article-title":"Rapid effects of aldosterone and spironolactone in the isolated working rat heart","volume":"40","author":"Barbato","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0040","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0045","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.102673599","article-title":"Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes","volume":"99","author":"Beggah","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0050","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0055","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ahj.2008.12.013","volume":"157","author":"Beygui","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0060","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/en.2011-2098","article-title":"Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis","volume":"153","author":"Bienvenu","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0065","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/0039-128X(94)00074-M","article-title":"Bidirectional activity of 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle cells","volume":"60","author":"Brem","year":"1995","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0070","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/01.HYP.31.1.459","article-title":"Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells","volume":"31","author":"Brem","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0075","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1210\/endo.142.4.8088","article-title":"Light and electron microscopy localization of the 11beta-hydroxysteroid dehydrogenase type I enzyme in the rat","volume":"142","author":"Brereton","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0080","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1210\/endo.137.2.8593833","article-title":"The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development","volume":"137","author":"Brown","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.yjmcc.2005.04.001","article-title":"Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo","volume":"39","author":"Burniston","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0090","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/01.HYP.0000154365.30593.d3","article-title":"Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src","volume":"45","author":"Callera","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0095","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.bjp.0706220","article-title":"Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?","volume":"145","author":"Chai","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0100","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/01.HYP.0000205831.39339.a5","article-title":"Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?","volume":"47","author":"Chai","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.25.1.117","article-title":"Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells","volume":"25","author":"Christ","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0110","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/01.CIR.99.11.1485","article-title":"Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells","volume":"99","author":"Christ","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0303-7207(02)00112-0","article-title":"Spironolactone increases integrin beta3 gene expression in kidney and heart muscle cells","volume":"194","author":"Chun","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1020640203862","article-title":"Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure","volume":"16","author":"Cittadini","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0303-7207(97)04000-8","article-title":"Ontogeny and sexual dimorphic expression of mouse type 2 11beta-hydroxysteroid dehydrogenase","volume":"127","author":"Condon","year":"1997","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5603\/CJ.2012.0043","article-title":"Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation","volume":"19","author":"Dabrowski","year":"2012","journal-title":"Cardiol J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0140","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1006\/jmcc.2002.2115","article-title":"Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat","volume":"34","author":"De Angelis","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/clc.20689","article-title":"Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation","volume":"33","author":"De-An","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0145","doi-asserted-by":"crossref","first-page":"H647","DOI":"10.1152\/ajpheart.2001.281.2.H647","article-title":"Effect of a selective aldosterone receptor antagonist in myocardial infarction","volume":"281","author":"Delyani","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/en.2010-0925","article-title":"11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe\u2212\/\u2212 mice","volume":"152","author":"Deuchar","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0155","doi-asserted-by":"crossref","first-page":"R944","DOI":"10.1152\/ajpregu.2001.281.3.R944","article-title":"Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats","volume":"281","author":"Dorrance","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0165","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/hrt.2004.046540","article-title":"Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction","volume":"91","author":"Enomoto","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0170","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1046\/j.1523-1755.2000.00976.x","article-title":"Mineralocorticoid selectivity: molecular and cellular aspects","volume":"57","author":"Farman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0175","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0180","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0185","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","article-title":"Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction","volume":"42","author":"Fraccarollo","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cardiores.2005.03.001","article-title":"Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction","volume":"67","author":"Fraccarollo","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0195","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/STROKEAHA.110.598441","article-title":"Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia","volume":"42","author":"Frieler","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/clpt.2011.227","article-title":"Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension","volume":"91","author":"Fujimura","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/01.HYP.0000171184.84077.80","article-title":"Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts","volume":"46","author":"Fujita","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-11-0372","article-title":"Mechanisms of ligand specificity of the mineralocorticoid receptor","volume":"213","author":"Fuller","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0220","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","article-title":"Mineralocorticoid receptors: distribution and activation","volume":"10","author":"Funder","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0230","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1210\/endo-125-4-2224","article-title":"Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors","volume":"125","author":"Funder","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0235","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/BF03346529","article-title":"Cardiac remodeling in patients with primary aldosteronism","volume":"32","author":"Galetta","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0245","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0895-7061(01)02331-7","article-title":"Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension","volume":"15","author":"Goldkorn","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0250","first-page":"221","article-title":"The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity","volume":"8","author":"Golestaneh","year":"2002","journal-title":"Mol Vis"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0255","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1210\/en.2004-0295","article-title":"Origin of aldosterone in the rat heart","volume":"145","author":"Gomez-Sanchez","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0260","first-page":"E649","article-title":"ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension","volume":"258","author":"Gomez-Sanchez","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000338166","article-title":"Inflammatory cytokines in heart failure: mediators and markers","volume":"122","author":"Gullestad","year":"2012","journal-title":"Cardiology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0270","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/01.HYP.33.5.1179","article-title":"11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension","volume":"33","author":"Hatakeyama","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pharmthera.2007.06.005","article-title":"Preconditioning and postconditioning: united at reperfusion","volume":"116","author":"Hausenloy","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0280","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2008.10.029","article-title":"Preconditioning and postconditioning: underlying mechanisms and clinical application","volume":"204","author":"Hausenloy","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0285","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0290","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1210\/mend-3-11-1886","article-title":"Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat","volume":"3","author":"Herman","year":"1989","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0295","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.0802886","article-title":"Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity","volume":"184","author":"Herrada","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0300","doi-asserted-by":"crossref","first-page":"H2491","DOI":"10.1152\/ajpheart.00840.2004","article-title":"Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI","volume":"288","author":"Huang","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0305","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.HYP.0000172622.51973.f5","article-title":"Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation","volume":"46","author":"Ishizawa","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0310","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2007.03.043","article-title":"Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model","volume":"566","author":"Iwanami","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0315","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2009","key":"10.1016\/j.pharmthera.2013.11.006_bb9000","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1752-8062.2009.00094.x","article-title":"Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction","volume":"2","author":"Kanashiro-Takeuchi","year":"2009","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0320","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/01.RES.0000244092.95152.86","article-title":"Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure","volume":"99","author":"Kang","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0325","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","article-title":"Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice","volume":"41","author":"Keidar","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0330","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1097\/HJH.0b013e328359862d","article-title":"Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension","volume":"30","author":"Kisaka","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0335","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jsbmb.2008.06.004","article-title":"Cloning of chicken 11beta-hydroxysteroid dehydrogenase type 1 and its tissue distribution","volume":"111","author":"Klusonova","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0340","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1210\/en.2008-1493","article-title":"Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart","volume":"150","author":"Klusonova","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0345","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/ajh.2010.91","article-title":"Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb","volume":"23","author":"Kobayashi","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0350","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.HYP.0000157408.43807.5a","article-title":"Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway","volume":"45","author":"Kobayashi","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0355","first-page":"906","article-title":"Effect of infarct size and site, patency of the infarct vessel and perfusion of vital myocardium on remodeling of the left ventricle\u2014studies with cine-magnetic resonance tomography in the first 6months following myocardial infarct","volume":"85","author":"Konermann","year":"1996","journal-title":"Z Kardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0360","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ajh\/7.1.100","article-title":"Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells","volume":"7","author":"Kornel","year":"1994","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0365","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1210\/endo-127-6-3009","article-title":"Characterization of 11 beta-hydroxysteroid dehydrogenase gene expression: identification of multiple unique forms of messenger ribonucleic acid in the rat kidney","volume":"127","author":"Krozowski","year":"1990","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.pharmthera.2013.11.006_bb0370","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCHEARTFAILURE.112.000173","article-title":"Clinical benefit of Eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study","volume":"6","author":"Krum","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0375","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cardiores.2004.08.004","article-title":"Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats","volume":"64","author":"Lal","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0380","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1159\/000178483","article-title":"Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat","volume":"29","author":"Lammers","year":"2012","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0385","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00210-010-0553-2","article-title":"Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits","volume":"382","author":"Laszlo","year":"2010","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0395","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","article-title":"Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Li","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0390","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0303-7207(96)03822-1","article-title":"Rat 11 beta-hydroxysteroid dehydrogenase type 2 enzyme is expressed at low levels in the placenta and is modulated by adrenal steroids in the kidney","volume":"120","author":"Li","year":"1996","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0400","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.surg.2011.02.006","article-title":"Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy","volume":"150","author":"Lin","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0405","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.exer.2011.12.012","article-title":"Activation of the aldosterone\/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia\u2013reperfusion injury","volume":"96","author":"Liu","year":"2012","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0410","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/HYPERTENSIONAHA.111.190488","article-title":"Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction","volume":"59","author":"Loan Le","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0415","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lombes","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0420","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1210\/endo.135.3.8070376","article-title":"The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase","volume":"135","author":"Lombes","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0425","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","article-title":"Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor","volume":"71","author":"Lombes","year":"1992","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0430","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0960-0760(02)00250-9","article-title":"Non-genomic aldosterone action: from the cell membrane to human physiology","volume":"83","author":"Losel","year":"2002","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0435","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","article-title":"Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment","volume":"90","author":"Macdonald","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0440","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/01.CIR.0000135599.33787.CA","article-title":"Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways","volume":"110","author":"Mano","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0445","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/eurheartj\/ehr064","article-title":"Relationship between location and size of myocardial infarction and their reciprocal influences on post-infarction left ventricular remodelling","volume":"32","author":"Masci","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0450","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2004.02.010","article-title":"Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction","volume":"10","author":"Masson","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0455","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1139\/Y07-017","article-title":"Non-genomic effects of aldosterone on intracellular ion regulation and cell volume in rat ventricular myocytes","volume":"85","author":"Matsui","year":"2007","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0460","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1253\/circj.68.376","article-title":"Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction","volume":"68","author":"Matsumoto","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0465","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jsbmb.2005.02.003","article-title":"11beta-hydroxysteroid dehydrogenase in the heart of normotensive and hypertensive rats","volume":"94","author":"Mazancova","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0470","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0475","doi-asserted-by":"crossref","first-page":"F78","DOI":"10.1152\/ajprenal.00077.2007","article-title":"Renal ischemia\u2013reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone","volume":"293","author":"Mejia-Vilet","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0480","doi-asserted-by":"crossref","first-page":"C175","DOI":"10.1152\/ajpcell.1998.274.1.C175","article-title":"Na+influx and Na(+)-K+ pump activation during short-term exposure of cardiac myocytes to aldosterone","volume":"274","author":"Mihailidou","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0485","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","article-title":"Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction","volume":"54","author":"Mihailidou","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0490","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1046\/j.1440-1681.2003.03906.x","article-title":"Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats","volume":"30","author":"Mill","year":"2003","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0495","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/eurheartj\/ehi478","article-title":"Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction","volume":"26","author":"Milliez","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0500","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0505","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1046\/j.1523-1755.2000.00967.x","article-title":"Expression of the 11beta-hydroxysteroid dehydrogenase 2 gene in the mouse","volume":"57","author":"Moore","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0510","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0515","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1210\/endo.139.6.6036","article-title":"Extranuclear localization of endogenous 11beta-hydroxysteroid dehydrogenase-2 in aldosterone target cells","volume":"139","author":"Naray-Fejes-Toth","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0520","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.yjmcc.2005.05.015","article-title":"Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure","volume":"39","author":"Nehme","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0525","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/hy0302.105295","article-title":"Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro","volume":"39","author":"Neumann","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0530","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/FJC.0b013e318258f8ce","article-title":"Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts","volume":"60","author":"Noda","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0535","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.steroids.2008.10.010","article-title":"Mineralocorticoid receptors: emerging complexity and functional diversity","volume":"74","author":"Odermatt","year":"2009","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0540","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.mce.2011.07.020","article-title":"Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: an overview","volume":"350","author":"Odermatt","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0545","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/me.2004-0331","article-title":"The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions","volume":"19","author":"Pascual-Le Tallec","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0550","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.CIR.0000138973.55605.38","article-title":"Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction","volume":"110","author":"Perrier","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0555","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0560","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0565","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0570","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy","volume":"85","author":"Ramires","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0575","doi-asserted-by":"crossref","first-page":"F932","DOI":"10.1152\/ajprenal.00252.2009","article-title":"Adrenalectomy prevents renal ischemia\u2013reperfusion injury","volume":"297","author":"Ramirez","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0580","doi-asserted-by":"crossref","DOI":"10.1177\/1470320312467558","article-title":"Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice","author":"Raz-Pasteur","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0585","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1139\/y03-081","article-title":"Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats","volume":"81","author":"Rochetaing","year":"2003","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0590","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1210\/endo.137.3.8603583","article-title":"Localization of 11beta-hydroxysteroid dehydrogenase type 2 in rat tissues: in situ studies","volume":"137","author":"Roland","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0595","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0960-0760(00)00034-0","article-title":"Cloning and expression of the bovine 11beta-hydroxysteroid dehydrogenase type-2","volume":"72","author":"Romero","year":"2000","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0605","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/1470320311415134","article-title":"Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition","volume":"12","author":"Rossi","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0600","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","article-title":"Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma","volume":"95","author":"Rossi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0610","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1093\/ndt\/gfs014","article-title":"Recovery from ischemic acute kidney injury by spironolactone administration","volume":"27","author":"Sanchez-Pozos","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0615","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1089\/ars.2005.7.1294","article-title":"Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences","volume":"7","author":"Sanz-Rosa","year":"2005","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0620","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.107.093450","article-title":"Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction","volume":"50","author":"Sartorio","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0625","first-page":"45","article-title":"Eplerenone improves vascular function and reduces platelet activation in diabetic rats","volume":"61","author":"Schafer","year":"2010","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0630","first-page":"761","article-title":"Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system","volume":"86","author":"Schmidt","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0635","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1055\/s-2005-837650","article-title":"Aldosterone blunts human baroreflex sensitivity by a nongenomic mechanism","volume":"113","author":"Schmidt","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0640","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/eurheartj\/ehp555","article-title":"Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion","volume":"31","author":"Schmidt","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0645","doi-asserted-by":"crossref","DOI":"10.1161\/01.HYP.0000105111.06482.7E","article-title":"Rapid nongenomic aldosterone effects in the human forearm?","volume":"43","author":"Schmitt","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0650","first-page":"E616","article-title":"Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells","volume":"272","author":"Schneider","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0655","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1006\/cbir.1997.0220","article-title":"Rapid aldosterone-induced cell volume increase of endothelial cells measured by the atomic force microscope","volume":"21","author":"Schneider","year":"1997","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0660","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0006-8993(91)91612-5","article-title":"Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus","volume":"561","author":"Seckl","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0665","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/endo.143.1.8583","article-title":"11beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart","volume":"143","author":"Sheppard","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0670","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1507\/endocrj.K10E-383","article-title":"Activation of Src-ATF1 pathway is involved in upregulation of Nox1, a catalytic subunit of NADPH oxidase, by aldosterone","volume":"58","author":"Shi","year":"2011","journal-title":"Endocr J"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0675","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","article-title":"Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis","volume":"99","author":"Silvestre","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0680","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pharmthera.2005.10.010","article-title":"Rapid actions of aldosterone in vascular health and disease\u2014friend or foe?","volume":"111","author":"Skott","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0695","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1006\/jmcc.1996.0072","article-title":"High affinity NAD(+)-dependent 11 beta-hydroxysteroid dehydrogenase in the human heart","volume":"28","author":"Slight","year":"1996","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0685","first-page":"180","article-title":"Glucocorticoid metabolism in the cardiac interstitium: 11 beta-hydroxysteroid dehydrogenase activity in cardiac fibroblasts","volume":"122","author":"Slight","year":"1993","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0690","first-page":"821","article-title":"Species diversity of 11 beta-hydroxysteroid dehydrogenase in the cardiovascular system","volume":"124","author":"Slight","year":"1994","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0700","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1440-1681.1996.tb01750.x","article-title":"11 beta-hydroxysteroid dehydrogenase type I enzyme in the hearts of normotensive and spontaneously hypertensive rats","volume":"23","author":"Smith","year":"1996","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0705","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1440-1681.1996.tb02776.x","article-title":"Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme","volume":"23","author":"Smith","year":"1996","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0710","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0039-128X(01)00148-9","article-title":"11 beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism","volume":"67","author":"Souness","year":"2002","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0715","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/jc.2005-0681","article-title":"Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I","volume":"90","author":"Stowasser","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0720","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/EJE-10-0709","article-title":"Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome","volume":"164","author":"Studen","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0730","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","article-title":"Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation","volume":"26","author":"Suzuki","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0725","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","article-title":"Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure","volume":"106","author":"Suzuki","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0735","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0740","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/03009740802279709","article-title":"Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis","volume":"38","author":"Syngle","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0745","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.HYP.0000184640.81730.22","article-title":"Eplerenone inhibits atherosclerosis in nonhuman primates","volume":"46","author":"Takai","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0755","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0960-0760(03)00216-4","article-title":"Pathophysiological roles of vascular 11beta-hydroxysteroid dehydrogenase and aldosterone","volume":"85","author":"Takeda","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0750","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1291\/hypres.30.427","article-title":"Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts","volume":"30","author":"Takeda","year":"2007","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0760","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jsbmb.2003.12.014","article-title":"Differential expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 mRNA and glucocorticoid receptor protein during mouse embryonic development","volume":"88","author":"Thompson","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0765","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1476-5381.2012.02194.x","article-title":"Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications","volume":"168","author":"Toda","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0770","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/er.2003-0031","article-title":"11beta-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response","volume":"25","author":"Tomlinson","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0775","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1172\/JCI62839","article-title":"Signaling effectors underlying pathologic growth and remodeling of the heart","volume":"123","author":"van Berlo","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0780","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2009.199","article-title":"Myocardial remodeling after infarction: the role of myofibroblasts","volume":"7","author":"van den Borne","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0785","first-page":"970","article-title":"Tissue-specific distribution of the NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase","volume":"131","author":"Walker","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0790","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1210\/endo-129-6-3305","article-title":"11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids","volume":"129","author":"Walker","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0800","doi-asserted-by":"crossref","first-page":"F1178","DOI":"10.1152\/ajprenal.00386.2003","article-title":"Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet","volume":"286","author":"Wang","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0805","doi-asserted-by":"crossref","first-page":"R1025","DOI":"10.1152\/ajpregu.00387.2011","article-title":"Impact of salt on cardiac differential gene expression and coronary lesion in normotensive mineralocorticoid-treated mice","volume":"302","author":"Wang","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0795","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1071-9164(03)00578-5","article-title":"Role of a selective aldosterone blocker in mice with chronic heart failure","volume":"10","author":"Wang","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0810","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/01.RES.76.6.973","article-title":"Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells","volume":"76","author":"Wehling","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0815","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1006\/bbrc.1994.2484","article-title":"Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: subcellular localization of calcium elevations by single cell imaging","volume":"204","author":"Wehling","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0820","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.steroids.2011.12.023","article-title":"Nongenomic actions of aldosterone and progesterone revisited","volume":"77","author":"Wendler","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0825","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0960-0760(92)90220-D","article-title":"Tissue localization of 11 beta-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor","volume":"41","author":"Whorwood","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0830","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1210\/en.2005-0370","article-title":"The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart","volume":"146","author":"Ye","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0835","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2013.11.006_bb0840","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jmri.23962","article-title":"Assessment of left ventricular myocardial scar in coronary artery disease by a three-dimensional MR imaging technique","volume":"38","author":"Yin","year":"2013","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0845","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0895-7061(96)00031-3","article-title":"Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension","volume":"9","author":"Yoshihara","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2013.11.006_bb0850","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813002246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813002246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T00:43:50Z","timestamp":1564879430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813002246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":171,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0163725813002246"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.11.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cardioprotective effects of mineralocorticoid receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}